Evidence map›Paper›PMID 41570246›Full record

ArticleMolecular pharmaceutics2026

Preclinical Study of CDH3-Targeted

Mingming Tang, Huayan Zhang, Huan Du, Xiaofei Hao, Binwei Lin, Yihan Zhu, Decai Wang, Wei Wu, Xiaobo Du

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular pharmaceutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Mingming TangClinical Medical School, North Sichuan Medical College, Nanchong 637000, China.
Huayan ZhangCollege of Life Sciences and Agri-forestry, Southwest University of Science and Technology, Mianyang 621000, China.
Huan DuMianyang Central Hospital, School of Medicine, University of Electronic Science and Technology of China, Mianyang 621000, China.
Xiaofei HaoMianyang Central Hospital, School of Medicine, University of Electronic Science and Technology of China, Mianyang 621000, China.
Binwei LinNHC Key Laboratory of Nuclear Technology Medical Transformation, Mianyang Central Hospital, School of Medicine, University of Electronic Science and Technology of China, Mianyang 621000, China.
Yihan ZhuSichuan Clinical Research Center for Radiation and Therapy, Mianyang Central Hospital, Mianyang 621000, China.
Decai WangSichuan Clinical Research Center for Radiation and Therapy, Mianyang Central Hospital, Mianyang 621000, China.
Wei WuSouthwest University of Science and Technology, Mianyang 621000, China.
Xiaobo DuMianyang Central Hospital, School of Medicine, University of Electronic Science and Technology of China, Mianyang 621000, China.ORCID 0000-0001-6348-0636

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Triple-negative breast cancer (TNBC) is characterized by poor prognosis, limited therapeutic options, and low survival rates, underscoring the urgent need for novel and effective treatment strategies. This study aimed to investigate the potential of CDH3 as a theranostic target for TNBC and to develop a CDH3-based targeted radionuclide theranostic approach. Flow cytometry was used to analyze CDH3 expression, and a CDH3-overexpressing HCC1806 xenograft mouse model was established. The performance of the dual-functional probe

Indexed as

CadherinsLutetiumRadioisotopesTriple Negative Breast NeoplasmsZirconiumAnimalsAntibodies, MonoclonalCell Line, TumorFemaleHumansMiceMice, NudePositron Emission Tomography Computed TomographyRadiopharmaceuticalsTheranostic NanomedicineTissue DistributionAntibodies, MonoclonalCadherinsCDH3 protein, humanLutetiumLutetium-177RadioisotopesRadiopharmaceuticalsZirconiumZirconium-89[177Lu]Lu-DOTA-11E10C1189Zr-DFO-11E10C11CDH3targeted radionuclide therapytriple-negative breast cancer

Identifiers

PMID41570246
PMCPMC12869492

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.